ALK gains European approval for Itulazax against allergic rhinitis

Denmark-based allergy specialist ALK-Abelló (ALKB: DC) says it has successfully completed the marketing authorization procedure for its tree sublingual allergy immunotherapy (SLIT) tablet in 17 European countries. Itulazax is expected to be the brand name of the tree SLIT-tablet.

Millions of Europeans suffer from tree pollen allergies. It is estimated that approximately 10% of allergic rhinitis sufferers have a condition which cannot be well controlled despite the use of symptom-relieving medication. For many of these patients, Itulazax will be a relevant treatment option which can improve their quality of life by addressing the underlying cause of their disease and not just the symptoms.

Itulazax is indicated in adult patients for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis, induced by pollen from the birch homologous family of trees, which also includes alder, beech, hazel, hornbeam and oak. Itulazax is indicated in patients with a clinical history of symptoms despite use of symptom-relieving medication and a positive test of sensitization to a member of the birch homologous group (skin prick test and/or specific IgE).